Institution:	Papillion Research Center/Avacare
Meeting Date:	December 11, 2025
Meeting Time	11:00 AM Central Time
Meeting Type:	Virtual Platform Teleconference (Remote) Open to the Public
Members in Attendance:	Member Voting Member Type Bavaret, Tammy Yes Chair: Biosafety Expert/HGT Expert Reed, Craig Yes Core Member: Biosafety Expert/HGT Expert Rastein, Daniel Yes Core Member: Biosafety Expert/HGT Expert Boesch, Brandon Yes Local Unaffiliated Member Diederich, Heather No Site Contact
Invited Members Not in Attendance:	Member Voting Member Type Crowder, Ken Yes Local Unaffiliated Member
Guests:	Kalili, Nicole
Staff:	Hemmelgarn, Marian

 

Call to Order: The IBC Chair called the meeting to order at 11:02 AM. A quorum was present as defined in the Sabai IBC Charter. 

 

Conflicts of Interest: The IBC Chair reminded all members present to identify any conflicts of interest (COI). No COI was declared by any voting member of the IBC for any of the items on the agenda.

 

Public Comments: No public comments were made prior to or at the meeting.

 

Review of Prior Business: None

 

Previous Meeting Minutes: Minutes from 1/31/25 were approved by the IBC with no changes.

 

New Business:

 

PI:	Doehner, Tamara MD
Sponsor:	Bavarian Nordic A/S
Protocol:	WEV-MVA-002 A Two-Stage, Randomized, Double-Blind, Dose Ranging Phase 2 Trial in Healthy Adult Participants to Investigate Optimal Dose and Dosing Regimen, and to Evaluate Safety and Immunogenicity of the Recombinant MVA BN WEV Vaccine
Review Type:	Annual Review
NIH Guidelines Section:	III-C-1

 

 

 

 

 

 

 

 

Trial Summary: WEV-MVA-002 is a placebo-controlled Phase 2 dose-ranging study sponsored by Bavarian Nordic A/S designed to assess the safety, reactogenicity and immunogenicity of

MVA-BN-WEV in healthy adult participants (≥18 to ≤50 years of age). MVA-BN-WEV (also known as MVA-mBN396) is a recombinant multivalent vaccine candidate intended for active immunization against disease induced by Venezuelan equine encephalitis virus (VEEV) and eastern equine encephalitis virus (EEEV) in persons at high risk of exposure. The investigational product (IP) is administered by intramuscular (IM) injection.

Biosafety Containment Level (BSL): The study agent MVA-BN-WEV is derived from a modified vaccinia virus Ankara (MVA) poxvirus. Poxviruses (excluding Monkeypox virus and restricted poxviruses) are classified as Risk-Group 2 agents under the NIH Guidelines; therefore, BSL2 is the recommended containment level.

 

Risk Assessment and Discussion:

• The Committee reviewed the clinical trial Sponsor’s study documents and the Sabai-generated comprehensive study-specific Risk Assessment which collectively provided a thorough description of the recombinant or synthetic nucleic acid molecules (investigational product/s) and the proposed clinical research activities involving the IP.
  • In summary, the primary risks in this clinical trial include potential occupational exposure from accidental needlestick, spills, and splashes of the IP during preparation and/or administration procedures. These potential risks are mitigated through a combination of relevant staff training, safe clinical practices (including Standard Precautions and sharps safety) and use of appropriate PPE (as prescribed in the Risk Assessment and documented in the IBC submission package).

   

  • The Site confirmed that only study personnel who have been educated on the potential biohazards and the precautions to be taken when working with the IP will handle the IP or any materials contaminated by the IP.
  • The Site confirmed that study personnel are sufficiently trained in the practices and techniques required to safely work with the IP.
  • The Site confirmed that staff members receive Bloodborne Pathogens training.
  • Occupational Health Recommendations: None
  • The Committee had no additional significant comments or recommendations regarding the description of the potential risks and occupational exposure hazards associated with handling the IP in this clinical trial, or the proposed mitigation strategies, as detailed in the Risk Assessment.

     

• The Committee reviewed the Site’s facility details, relevant study-specific procedures and practices, the Annual Review Report, and other applicable information provided by the Site for the purposes of the IBC review.
  • The Site verified that the information provided by the Chair was accurate.
  • The Site confirmed the accuracy of the Annual Review Report.
  • The Committee noted that the Site map did not show a door to the Lab. The Site confirmed that the lab has a door as seen in the Site photos.

 

Motion: A motion of Full Approval for the study at BSL-2 was passed by unanimous vote.

 

• Contingencies stated by the Committee: None

   

• Stipulations stated by the Committee: None

 

Review of Incidents: Nothing to report.

 

IBC Training: Nothing to report.

Reminder of IBC Approval Requirements.

Adjournment: The IBC Chair adjourned the meeting at 11:32 AM

Post-Meeting Pre-Approval Note: None

 

Institution:	Versailles Family Medicine/Avacare
Meeting Date:	January 13, 2026
Meeting Time	10:30 AM Eastern Time
Meeting Type:	Virtual Platform Teleconference (Remote) Open to the Public
Memers in Attendance:	Member Voting Member Type Bavaret, Tammy Yes Chair: Biosafety Expert/HGT Expert Helm, Allen Yes Core Member: Biosafety Expert/HGT Expert Rastein, Daniel Yes Core Member: Biosafety Expert/HGT Expert Hayman, Robert Yes Local Unaffiliated Member Mazzetti, Delena Yes Local Unaffiliated Member Cooper, Shelley No Site Contact
Invited Members Not in Attendance:	None
Guests:	None
Staff:	Payne, Kaylie

 

Call to Order: The IBC Chair called the meeting to order at 10:30 AM. A quorum was present as defined in the Sabai IBC Charter. 

 

Conflicts of Interest: The IBC Chair reminded all members present to identify any conflicts of interest (COI). No COI was declared by any voting member of the IBC for any of the items on the agenda.

 

Public Comments: No public comments were made prior to or at the meeting.

 

Review of Prior Business: None

 

Previous Meeting Minutes: Previous meeting minutes from 1-22-25 were reviewed and approved with no changes requested.

 

New Business:

PI:	Smith, Brian MD
Sponsor:	Bavarian Nordic A/S
Protocol:	WEV-MVA-002 A Two-Stage, Randomized, Double-Blind, Dose Ranging Phase 2 Trial in Healthy Adult Participants to Investigate Optimal Dose and Dosing Regimen, and to Evaluate Safety and Immunogenicity of the Recombinant MVA BN WEV Vaccine.
Review Type:	Annual Review
NIH Guidelines Section:	III-C-1

 

 

 

 

 

 

 

 

Trial Summary: WEV-MVA-002 is a placebo-controlled Phase 2 dose-ranging study sponsored by Bavarian Nordic A/S designed to assess the safety, reactogenicity and immunogenicity of MVA-BN-WEV in healthy adult participants (≥18 to ≤50 years of age). MVA-BN-WEV (also known as MVA-mBN396) is a recombinant multivalent vaccine candidate intended for active immunization against disease induced by Venezuelan equine encephalitis virus (VEEV) and eastern equine encephalitis virus (EEEV) in persons at high risk of exposure. The investigational product (IP) is administered by intramuscular (IM) injections.

Biosafety Containment Level (BSL): The study agent MVA-BN-WEV is derived from a modified vaccinia virus Ankara (MVA) poxvirus. Poxviruses (excluding Monkeypox virus and restricted poxviruses) are classified as Risk-Group 2 agents under the NIH Guidelines; therefore, BSL2 is the recommended containment level.

 

Risk Assessment and Discussion:

• The Committee reviewed the clinical trial Sponsor’s study documents and the Sabai-generated comprehensive study-specific Risk Assessment which collectively provided a thorough description of the recombinant or synthetic nucleic acid molecules (investigational product/s) and the proposed clinical research activities involving the IP.
  • In summary, the primary risks in this clinical trial include potential occupational exposure from accidental spills or splashes of the IP during preparation and/or administration procedures and needlesticks due to the use of needles during preparation and/or administration. These potential risks are mitigated through a combination of relevant staff training, safe clinical practices (including Standard Precautions and sharps safety) and use of appropriate PPE (as prescribed in the Risk Assessment and documented in the IBC submission package).

   

  • The Site confirmed that only study personnel who have been educated on the potential biohazards and the precautions to be taken when working with the IP will handle the IP or any materials contaminated by the IP.
  • The Site confirmed that study personnel are sufficiently trained in the practices and techniques required to safely work with the IP.
  • The Site confirmed that staff members receive Bloodborne Pathogens training.
  • Occupational Health Recommendations: None
  • The Committee had no additional significant comments or recommendations regarding the description of the potential risks and occupational exposure hazards associated with handling the IP in this clinical trial, or the proposed mitigation strategies, as detailed in the Risk Assessment.

     

• The Committee reviewed the Site’s facility details, relevant study-specific procedures and practices, the Annual Review Report and other applicable information provided by the Site for the purposes of the IBC review.
  • The Site verified that the information provided by the Chair was accurate.
  • The Committee stipulated that the site provide a larger overview photo of the Biohazardous Waste Storage area and confirm that the biohazard signage is appropriate. The Site had no concerns and will provide that photo.

 

Motion: A motion of Approval with Stipulations for the study at BSL-2 was passed by unanimous vote. There were no votes against and no abstentions.

 

• Contingencies stated by the Committee: None
• Stipulations stated by the Committee:

The Site provides an overview photo of the Biohazardous Waste storage area by 2/12/2026. The Committee agreed that resolution of this stipulation can be approved following review by the AP.

 

Review of Incidents: Nothing to report.

IBC Training: Nothing to report

Reminder of IBC Approval Requirements.

Adjournment: The IBC Chair adjourned the meeting at 11:05 AM

Post-Meeting Pre-Approval Note: None